Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
Telix Climbs on ASX as Investors Look Beyond Its Diagnostics Business
Highlights
Telix Pharmaceuticals Limited (ASX: TLX) presented its expansion priorities on 4 November 2026, highlighting opportunities across cancer diagnostics, therapeutic development and manufacturing. The company’s shares traded at a current market price (CMP) of AU$13.720, representing a surge of 5.5%. Attention now turns to whether its established imaging business can underpin broader commercial success.
Commercial Growth Funds Pipeline Progress
Telix continues to forecast FY2026 revenue of US$950–970 million, plus US$40 million in other income. Annual revenue reached US$804 million in 2025, compared to US$517 million in 2024. The upper end of guidance implies approximately 20% growth.
First-half 2026 net profit after tax totalled US$38 million, while the Precision Medicine business achieved a 65% gross margin. Cash holdings were US$252 million at 30 June 2026. Planned research and development expenditure for FY2026 remains US$240–260 million.
Imaging Portfolio Extends Market Reach
The company’s FDA-approved imaging portfolio comprises Illuccix, Gozellix and Pixclara. Illuccix is commercially available in 22 countries, supported by a wider network of 45 manufacturing and distribution locations.
Development opportunities include kidney cancer imaging product Zircaix, prostate cancer diagnostic BiPASS and neuroendocrine tumour treatment candidate ITM-11. Their commercial contribution depends on regulatory outcomes and development progress.
ITM Offers Another Growth Avenue
Completion of the proposed ITM transaction is anticipated during FY2026, subject to shareholder approval, regulatory clearance and customary conditions.
ITM’s expected 2026 revenue is approximately US$300 million, compared to US$273 million in 2025. Manufacturing gross margins exceed 40%, although adjusted EBITDA recorded a US$12 million first-half loss.
Telix anticipates positive EBITDA contributions from 2027 and aims to capture US$50 million in synergies within two years.
Outlook
Key 2027 developments include TLX591-Tx’s interim futility analysis, TLX597-Tx OPTIMAL-PSMA results, TLX090-Tx Part A findings and BiPASS data. BiPASS could reach the market in late 2027 or 2028, conditional on approval. Sustained diagnostic sales, clinical execution and ITM integration will influence progress. However, trial results and regulatory decisions remain uncertain, and Telix has not provided formal FY2027 revenue guidance.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au